SCHEDULE 13G/A: Janus Henderson Group Discloses 10.1% Beneficial Stake in Larimar Therapeutics

Janus Henderson Group PLC and its affiliated entities have reported a combined beneficial ownership of 10.1% in Larimar Therapeutics, Inc. as of December 31, 2024.

Summary

• Janus Henderson Group PLC, a global asset manager, reported beneficial ownership of 6,443,286 shares of Larimar Therapeutics, Inc. Common Stock.
• This aggregate amount represents 10.1% of the outstanding class of Larimar Therapeutics' common stock.
• Janus Henderson Biotech Innovation Master Fund Ltd, an indirect subsidiary of Janus Henderson Group PLC, is specifically noted as beneficially owning 5,448,687 shares, which constitutes 8.5% of the class.
• The shares are held with shared voting power and shared dispositive power by both reporting entities.
• The filing, an Amendment No. 3 to Schedule 13G, certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive institutional investment by a reputable fund, which is generally viewed as a positive signal of confidence in the company. No negative information is presented.

Positives

• A significant institutional investor, Janus Henderson Group PLC, maintains a substantial 10.1% stake in Larimar Therapeutics, Inc., indicating continued institutional confidence.
• The investment is stated to be in the ordinary course of business and not for control purposes, suggesting a passive, long-term investment strategy by a major fund.

Negatives

• No specific negatives regarding Larimar Therapeutics' operational performance or financial health are disclosed in this beneficial ownership filing.

Risks

• This filing, a Schedule 13G, primarily concerns beneficial ownership disclosure and does not contain information regarding specific operational, financial, or market risks pertinent to Larimar Therapeutics, Inc.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing indicates continued institutional interest in Larimar Therapeutics, Inc., which is common for publicly traded companies, particularly those in the biotechnology sector that attract specialized investment funds like Janus Henderson Biotech Innovation Master Fund Ltd.

Comparison to Industry Standards

• This filing is a standard beneficial ownership disclosure required by the SEC when an entity acquires more than 5% of a company's stock.
• A 10.1% stake by a prominent institutional investor like Janus Henderson Group PLC is considered a significant position, demonstrating a notable investment in Larimar Therapeutics, Inc.
• The document does not provide specific comparable companies, projects, or results for direct industry comparison.

Stakeholder Impact

• Shareholders may interpret the significant stake held by Janus Henderson Group PLC as a positive indicator of institutional confidence in Larimar Therapeutics, Inc.'s long-term prospects.

Next Steps

• No specific future actions, events, or milestones for Larimar Therapeutics, Inc. are mentioned in this beneficial ownership filing.

Key Dates

Recommendation

Keywords

Larimar Therapeutics, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotech, Pharmaceuticals